In stark contrast to what has been obtained for cutaneous melanoma, targeted therapy using MAP-kinase and MEK-inhibitors [11] and immunotherapy [56] have shown little to no activity in clinical trials for the treatment of metastatic uveal melanoma. Here, MAP2K7 is linked to cutaneous melanoma.